Archive/Validation of an Automated AI Algorithm for the Quantification of Major OCT Parameters in Retinal Vein Occlusion–Related Macular Edema
Validation of an Automated AI Algorithm for the Quantification of Major OCT Parameters in Retinal Vein Occlusion–Related Macular Edema
Adriano Carnevali, Domenico Chisari, Raffaella Gioia et al.
May 7, 2026
en

Abstract

Background/Objectives: Retinal vein occlusion (RVO) commonly causes vision loss from macular edema (ME). OCT biomarkers (IRF, SRF, HRF, and ELM/EZ disruption) inform prognosis and treatment but are rarely quantified routinely due to time burden and interobserver variability. We aimed to validate a deep-learning algorithm for automated detection and quantification of key OCT biomarkers in RVO-ME versus expert assessment. Methods: In this retrospective single-center study, 93 eyes with RVO-ME imaged with spectral-domain OCT were analyzed. The AI quantified IRF/SRF volumes, ELM/EZ interruption, and HRF counts. Two masked expert clinicians provided reference evaluations. Performance and agreement were assessed using ROC AUC, Cohen’s kappa, intraclass correlation coefficient (ICC), Pearson correlation, and Bland–Altman analysis. Image-quality metrics (foveal centration and retinal layer segmentation) were recorded. Results: The AI showed high diagnostic performance (AUC: SRF 0.969; ELM 0.871; EZ 0.958) and substantial-to-almost-perfect agreement (kappa: SRF 0.807; ELM 0.788; EZ 0.914). HRF quantification correlated strongly with experts (r = 0.89, p < 0.001), with very good agreement (ICC = 0.87) and minimal bias. Image-quality accuracy exceeded 98% for foveal centration and layer segmentation. Conclusions: This AI software enables reliable, rapid automated assessment of major OCT biomarkers in RVO-ME, supporting streamlined personalized management; prospective studies should confirm longitudinal monitoring and treatment-guidance value.

IPC Classification

G06A61

Keywords

validationautomatedalgorithmquantificationmajorparametersretinalveinocclusionrelatedmacularedemajournalclinicalmedicinebackgroundobjectivescommonlycausesvisionlossbiomarkersdisruptioninform
Reference this publication

€ 4.00